Aktis Oncology IPO: revenue, losses and offering terms from its S-1
Aktis Oncology priced its IPO at $18 a share on 9 Jan 2026 and raised $318 million. Its shares trade on Nasdaq as AKTS. Revenue was $1.5 million in 2024, with a net loss of $44.0 million.
Headlines
- Revenue, 2024
- $1M
- Net loss, 2024
- $44M
- Revenue, First nine months of 2025
- $5M
- Up 8.4 times on a year earlier
- IPO price
- $18
- $318M raised
Aktis Oncology IPO terms
From the final prospectus (424B4).
- Exchange
- Nasdaq Global Select Market
- Ticker
- AKTS
- IPO price
- $18
- Shares offered
- 17,650,000
- Raised
- $318M
- Registered
- $365M, the amount the filing fee is paid on
- Underwriters
- J.P. Morgan, BofA Securities, Leerink Partners and TD Cowen
- First filed
- 19 Dec 2025
Aktis Oncology revenue and profit
| Period | Revenue | Operating income | Net income |
|---|---|---|---|
| 2024 | $1M | -$52M | -$44M |
| First nine months of 2024 | $554,000 | - | - |
| First nine months of 2025 | $5M | -$57M | -$49M |
Aktis Oncology share structure and company facts
- Share classes and votes
- Common stock: 1 vote per share, Class A common stock: 0 votes per share
- Employees
- 76
- Headquarters
- Boston, Massachusetts
Aktis Oncology shares since the IPO
Latest close 26 Oct 2026
- IPO price
- $18
- Priced 9 Jan 2026
- First close
- $22.40
- +24% on the IPO price
- Latest close
- $15.73
- -13% on the IPO price
Aktis Oncology's IPO filings
The registration statement, each amendment and the final prospectus, oldest first.
About the data
- Terms and financials are read from Aktis Oncology's newest prospectus (424B4 filed 9 Jan 2026) by a Kadoa workflow. Check figures that matter against the filing.
- Registered is the amount the filing fee is paid on, often a placeholder before the price range is set.
- Raised is the IPO price times the shares sold, without the underwriters' option. Trading compares the first and latest close with the IPO price.